No Data
Kobayashi Pharmaceutical: Extraordinary Report
Kobayashi Pharmaceutical: Notice regarding dividends from surplus
Japan paper, NRI, ETC (additional) Rating
Upgraded - Bullish Code Stock Name Brokerage Firm Previous Change After --------------------------------------------------------- <3861> Oji Holdings Nomura "Neutral" "Buy" Downgraded - Bearish Code Stock Name Brokerage Firm Previous Change After --------------------------------------------------------- <4477> BASE Daiwa "2" "3"
Rating Information (Target Price Change - Part 1) = Rengo, Gifty, ETC.
◎Nomura Securities (three-stage: Buy > neutral > Reduce) Rengo <3941.T> -- "Buy" to "Buy", 1370 yen to 1110 yen NRI <4307.T> -- "Buy" to "Buy", 5500 yen to 6000 yen KOKUSAI <6525.T> -- "Buy" to "Buy", 3700 yen to 3750 yen Panasonic <6752.T> -- "Buy" to "Buy", 2300 yen to 2500 yen Menicon <7780.T> -- "Buy" to "B
Announcement of individual stocks regarding the resolution results of the extraordinary shareholder meeting.
Announcement regarding the resolution results of the extraordinary shareholder meeting held on February 19, 2025. This is to inform you of the resolution results of our extraordinary shareholder meeting held today as follows. Item No. 1 (Shareholder Proposal) Regarding the appointment of a person to investigate the status of our business and property as stipulated in Article 316, Paragraph 2 of the Companies Act. This proposal was rejected. Item No. 2 (Shareholder Proposal) Regarding the appointment of three directors. This proposal was rejected. For an overview of the proposals, please refer to our press release dated January 21, 2025.
Glass Lewis ESG Controversy Alert: Kobayashi Pharmaceutical
